170 related articles for article (PubMed ID: 27340881)
21. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
[TBL] [Abstract][Full Text] [Related]
22. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
Rosen CJ; Chesnut CH; Mallinak NJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
[TBL] [Abstract][Full Text] [Related]
23. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
[TBL] [Abstract][Full Text] [Related]
24. Use of hormone replacement therapy for correction of high turnover bone disease in hypogonadal β-Thalassemia major patients presenting with osteoporosis: comparison with idiopathic premature ovarian failure.
Chatterjee R; Katz M; Bajoria R
Hemoglobin; 2011; 35(5-6):653-8. PubMed ID: 22074125
[TBL] [Abstract][Full Text] [Related]
25. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
26. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Alexandersen P; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
[TBL] [Abstract][Full Text] [Related]
27. Standard hormone therapy is inadequate for bone density in premature ovarian insufficiency.
Giraldo H; Benetti-Pinto C; Ferreira V; Garmes H; Yela D; Giraldo P
Gynecol Endocrinol; 2017 Apr; 33(4):283-286. PubMed ID: 27910707
[TBL] [Abstract][Full Text] [Related]
28. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
[TBL] [Abstract][Full Text] [Related]
29. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
Lindsay R; Cosman F; Lobo RA; Walsh BW; Harris ST; Reagan JE; Liss CL; Melton ME; Byrnes CA
J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
[TBL] [Abstract][Full Text] [Related]
30. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of hormone replacement therapy on bone mineral density and axial transmission ultrasound measurements in cortical bone.
Knapp KM; Blake GM; Spector TD; Fogelman I
Osteoporos Int; 2003 Jun; 14(4):289-94. PubMed ID: 12730793
[TBL] [Abstract][Full Text] [Related]
32. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
34. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
35. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
36. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis.
Ormarsdóttir S; Mallmin H; Naessén T; Petrén-Mallmin M; Broomé U; Hultcrantz R; Lööf L
J Intern Med; 2004 Jul; 256(1):63-9. PubMed ID: 15189367
[TBL] [Abstract][Full Text] [Related]
37. Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β-estradiol in comparison to levonorgestrel/ethinylestradiol.
Sørdal T; Grob P; Verhoeven C
Acta Obstet Gynecol Scand; 2012 Nov; 91(11):1279-85. PubMed ID: 22762147
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women.
Hart DM; Farish E; Fletcher CD; Barnes JF; Hart H; Nolan D; Spowart K
Osteoporos Int; 1998; 8(4):326-32. PubMed ID: 10024902
[TBL] [Abstract][Full Text] [Related]
39. Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy.
Yim CH; Choi JT; Choi HA; Kang YS; Moon IG; Yoon HK; Han IK; Kang DH; Han KO
J Bone Miner Metab; 2005; 23(5):395-400. PubMed ID: 16133690
[TBL] [Abstract][Full Text] [Related]
40. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
Greenspan SL; Resnick NM; Parker RA
J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
